REFRACTORY HEPATOCELLULAR CARCINOMA
Clinical trials for REFRACTORY HEPATOCELLULAR CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HEPATOCELLULAR CARCINOMA trials appear
Sign up with your email to follow new studies for REFRACTORY HEPATOCELLULAR CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for young cancer patients: experimental drug targets tough tumors
Disease control Recruiting nowThis study tests a drug called tegavivint in children, teens, and young adults (ages 1 to 30) whose solid tumors have returned or not responded to standard therapy. The drug works by blocking a key signal that tells cancer cells to grow. The trial aims to find the safest dose, un…
Matched conditions: REFRACTORY HEPATOCELLULAR CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated May 26, 2026 04:48 UTC
-
New drug combo aims to shrink tough liver tumors
Disease control Recruiting nowThis study tests whether two drugs, ligufalimab and cadonilimab, can shrink advanced liver or bile duct cancers that have stopped responding to standard treatments. About 64 adults will receive the drug combination to see if tumors get smaller. The goal is to find a new option fo…
Matched conditions: REFRACTORY HEPATOCELLULAR CARCINOMA
Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated May 20, 2026 11:53 UTC